Informational Only · Not Medical Advice · Consult a Dermatologist · Editorial Policy

The 2026 Global Delphi Consensus on Acne and the Microbiome: Evidence Limits and Open Questions for People With Acne-Prone Skin

The 2026 Global Delphi Consensus on Acne and the Microbiome concludes that the microbiome helps drive acne and deserves a place in treatment. Evidence limits mean probiotics, prebiotics and related approaches remain promising but unproven for routine care. A Delphi consensus is a structured survey where international experts vote in rounds until they reach agreement. The microbiome means the communities of bacteria and other microbes that live on skin and in the gut.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What the experts agreed on

The panel unanimously agreed that the microbiome contributes to acne development and that microbiome-targeted treatments should be adopted for management, according to the 2026 consensus paper in Pharmaceuticals. Unanimous agreement is rare in acne care and signals a shift in expert thinking. A large majority, 89%, also agreed that the microbiome influences acne severity and that the gut-skin connection directly affects acne.

The same majority said prebiotics, probiotics and postbiotics have potential benefit in therapy. Potential benefit is not the same as proven benefit. The panel framed these approaches as candidates for prevention and treatment, not replacements for established drugs.

Which bacteria change matters in acne

Acne does not come from having more Cutibacterium acnes overall than clear skin. Research finds loss of C. acnes phylotype diversity with enrichment of pro-inflammatory type IA1 strains, described in the 2025 Molecules review.

Phylotype means a closely related subgroup within one bacterial species. In acne-prone skin, protective subgroups decline while IA1 strains dominate and promote inflammation. That distinction matters for daily care. Protecting diversity matters more than stripping all bacteria from the skin.

Why guidelines remain cautious

The 2024 American Academy of Dermatology acne guidelines found evidence too limited to recommend probiotics, vitamins, dietary changes, peels, light devices or microbiology testing, as summarized by Medical Dialogues reporting on the JAAD guidelines. The guidelines identified those options as gaps needing long-term randomized trials. The 2026 consensus authors set similar boundaries.

They state that microbiome assessment methods need standardization and that long-term safety and efficacy of probiotic, postbiotic and other emerging therapies remain unevaluated. For readers, the message is consistent across both sources. Expert interest is high, but testing methods differ and durable results are still missing.

How to protect microbial diversity now

For acne-prone skin, the practical approach is to limit disruption while treating acne effectively. A December 2025 Medicina systematic review links protection of microbial diversity to shorter antibiotic courses combined with non-antibiotic treatment, reported in the Medicina systematic review.

Ask your clinician about these points: Bring a list of current cleansers, leave-on products and prior antibiotic courses to that visit. That record helps the clinician shorten exposure and select a combination regimen.

  • limit a systemic antibiotic to the shortest effective course, typically 12 weeks or less
  • combine it with benzoyl peroxide, a retinoid, or both when prescribed
  • choose non-disruptive skincare that does not strip or irritate the barrier

You Might Also Like

We use cookies to run this site, measure how it’s used, and show ads. Choose “Essentials only” to limit cookies to what the site needs to work. Privacy Policy.